Non-small Cell Lung Cancer - Enrollment Completed
1 clinical trials · Condition
◉ Watch Non-small Cell Lung Cancer - Enrollment Completed
| Record | Firm | Date |
|---|---|---|
| Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (NCT02122861) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-05-30 |
Track Non-small Cell Lung Cancer - Enrollment Completed automatically
Every clearance here is in the API, with alerts when new ones post.